Yoichi Hiasa

Professor

Ehime University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (32)

Background Findings regarding long‐term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real‐world clinical settings. Methods This multicenter retrospective study included 555 patients with Child‐Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression‐free survival (PFS), overall survival (OS), post‐progression survival (PPS), and immune‐related adverse events (irAEs) were analyzed. Results Median age was 73 years and 80.2% were male. Atez/Bev was given as first‐line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first‐line therapy showed a higher 3 year survival rate of 35.9%. Post‐progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%). Conclusions uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long‐term survival with a 3 year survival rate of approximately 30%, including 35.9% for first‐line users.

Year:

2026

Aims To determine whether the performance of leucine‐rich α2‐glycoprotein (LRG) as a biomarker for disease activity in patients with ulcerative colitis (UC) may depend on the extent of the disease. Methods and Results We evaluated the correlation between various biomarkers, including the serum biomarker LRG, and endoscopic activity in 171 patients with UC. Patients were categorized into two groups based on disease extent: patients with pancolitis and those with left‐sided colitis and proctitis. LRG demonstrated similar diagnostic accuracy compared to fecal markers in patients with UC exhibiting pancolitis (area under the curve [AUC] for predicting endoscopic mucosal healing: LRG, 0.92; fecal immunochemical testing [FIT], 0.95; and fecal calprotectin [Fcal], 0.96) (FIT vs. LRG, p = 0.886; Fcal vs. LRG, p = 0.412). Conversely, for patients with left‐sided colitis and proctitis, fecal markers outperformed LRG in predicting endoscopic mucosal healing (AUC: LRG, 0.66; FIT, 0.94; and Fcal, 0.92) (FIT vs. LRG, p < 0.001; Fcal vs. LRG, p = 0.004). Conclusion Our results support selecting biomarkers according to disease extent for the management of inflammatory bowel disease. In patients with UC and pancolitis, LRG is a viable alternative when fecal samples are not feasible. Conversely, for patients with left‐sided colitis and proctitis, fecal markers with high diagnostic accuracy are recommended.

Year:

2026

Aim Evidence regarding the optimal first‐line immune checkpoint inhibitor (ICI) regimen for treating unresectable hepatocellular carcinoma (uHCC) with Child–Pugh class B (CP‐B) liver function remains limited. This study compared atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre group) in real‐world settings. Methods In this multicenter retrospective study, 211 consecutive patients with uHCC and CP‐B liver function who underwent ICI‐based therapy as a first‐line therapy were analyzed. Treatment responses, survival outcomes, albumin–bilirubin (ALBI) score changes, and adverse events were evaluated. Survival analyses were adjusted using inverse probability weighting (IPW). Results The median progression‐free survival associated with the Atez/Bev and Dur/Tre regimens was 5.0 and 3.5 months, respectively; the median corresponding overall survival was 10.5 and 12.4 months. After IPW adjustment, no significant differences were observed in progression‐free or overall survival. The Atez/Bev regimen‐associated disease control rate was significantly higher (75.2% vs. 55.0%, p = 0.02). The Dur/Tre regimen, meanwhile, was associated with a significantly higher immune‐related adverse event incidence (10.5% vs. 32.7%, p < 0.01) and a greater need for high‐dose corticosteroid treatment. In contrast, the Atez/Bev regimen resulted in a progressive decrease in ALBI scores, whereas the Dur/Tre regimen maintained the hepatic functional reserve. Conclusions The Atez/Bev and Dur/Tre regimens afforded comparable survival outcomes but differed substantially in safety and effects on the hepatic functional reserve. Given the trade‐off between immunotoxicity and liver function preservation, treatment selection for CP‐B liver function should be individualized, considering baseline hepatic reserve, tolerability, and anticipated treatment trajectory.

Year:

2026

Aim Although Japanese expert consensus introduced the borderline resectable (BR) criteria, additional classification is considered necessary for clinical practice. This study aimed to evaluate the prognostic predictive value of the modified BR (mBR) criteria. Methods From 2009 to 2024, 1056 treatment‐naïve patients with hepatocellular carcinoma (HCC) and Child‐Pugh A were enrolled (median age: 73 years). To obtain the mBR criteria, the original BR classification was modified by separately considering patients with extrahepatic metastasis (EHM, termed “boldly BR”) ( n = 42) while categorizing the rest into resectable ( n = 790), mBR1 ( n = 95), and mBR2 ( n = 129) groups. Treatments were classified as Cur (curative: surgical resection or radiofrequency ablation), NC (non‐curative: other treatment), or BSC (best supportive care). Clinical features and prognosis according to mBR criteria were analyzed retrospectively. Results Overall survival (OS) was stratified according to the mBR criteria (resectable/mBR1/mBR2/BBR = 113.3/49.4/30.1/10.3 months). Albumin‐bilirubin scores worsened progressively, according to the criteria (−2.70/−2.54/−2.40/−2.37), and elevated tumor marker levels (alpha‐fetoprotein [AFP] levels ≥ 100 ng/mL: 18.5%/35.8%/46.5%/59.5%; AFP‐L3 ≥ 10%: 19.8%/40.9%/54.7%/66.7%; and des‐gamma‐carboxy prothrombin levels ≥ 100 mAU/mL: 35.8%/67.4%/81.4%/90.5%, each p < 0.001) occurred more frequently in advanced groups. The Cur group in the resectable category showed significantly better OS compared with the NC and BSC groups (121.3/48.1/35.3 months, p < 0.001). Similar trends occurred in mBR1 (66.5/34.2/5.2 months) and mBR2 (57.3/22.4/7.5 months). Conversely, although some patients in the curative group had long‐term survival, treatment modality and baseline characteristics showed no prognostic impact on BBR (15.0/10.3/9.0 months). Conclusion Other than for patients with EHM, aggressive surgical resection may be considered a potential initial therapeutic option for advanced HCC; however, direct comparisons with other treatment modalities were not performed in this study.

Year:

2025

Aims Higher levels of remnant cholesterol (Rem‐C) are associated with diabetic conditions, serving as a treatment target and surrogate marker for identifying high‐risk groups for diabetes mellitus (DM) onset. However, the effect of Rem‐C on DM onset based on sex and age remains unclear. We aimed to examine the association between Rem‐C levels and DM onset, stratified by sex and age. Methods In this health checkup‐based retrospective cohort study, we analyzed data from 13,952 participants who underwent medical checkups two or more times at the Ehime General Health Care Association between April 2003 and March 2021, a non‐hospital facility where health care services are provided to company employees and local residents. The mean follow‐up period was 4.66 years. Cox proportional hazard models were used to assess the association between Rem‐C and DM onset. Results In the multivariate analysis, higher Rem‐C levels were associated with DM onset in individuals aged <50 years (men: adjusted hazard ratio [aHR] = 1.81, 95% CI: 1.46–2.20; women: aHR = 2.13, 95% CI: 1.18–3.37). However, this association was not observed in those aged ≥50 years. Triglycerides (TG) were also significantly associated with DM onset in younger adults, with slightly higher predictive ability (AUC) than Rem‐C, particularly among younger women. Sensitivity analyses using continuous age as a variable showed similar trends. Conclusions Rem‐C and TG may be useful predictors of DM onset in younger adults, with TG showing slightly better performance. Age‐specific strategies may improve early DM prevention.

Year:

2025

Aim/Background This study aimed to validate the CLEAR score, a simple prognostic tool for hepatocellular carcinoma (HCC) patients undergoing atezolizumab plus bevacizumab (Atez/Bev) therapy, based on serum lactate dehydrogenase (LDH) and C‐reactive protein (CRP) levels. Materials/Methods From 2020 to 2023, 498 Japanese HCC patients receiving Atez/Bev therapy were enrolled. They were divided into a training set ( n = 280; 13 designated cancer care hospitals) and a validation set ( n = 218; 11 universities and their affiliated Japanese hospitals). In the training set, prognostic factors were analysed, leading to the development of the CLEAR score, which was then evaluated on the validation set. Results Baseline LDH beyond the upper normal limit (hazard ratio [HR] 1.97, 95% CI 1.48–2.64) and CRP (≥ 0.50 mg/dL) (HR 1.61, 95% CI 1.19–2.00) were identified as independent prognostic factors on multivariate analysis and used in the CLEAR score. In the training set, the median progression‐free survival (PFS) times in patients with scores 0, 1 and 2 were 11.1 months, 9.1 months and 3.3 months, respectively ( p < 0.001). The median overall survival (OS) times in patients with scores 0, 1 and 2 were not available, 15.3 months and 10.6 months, respectively ( p < 0.001). Similar results were obtained in the validation set (median PFS and OS times for scores 0, 1 and 2 = 9.4, 6.9 and 4.3 and 30.6, 20.8 and 8.9 months, respectively, each p < 0.001). Conclusion The CLEAR score provides a distinct and simple prediction of the prognosis of HCC patients receiving Atez/Bev therapy.

Year:

2025

Aims This study aimed to evaluate the therapeutic efficacy of durvalumab and tremelimumab (Dur/Tre) in patients with hepatocellular carcinoma (HCC) who had a tumor thrombus in the main portal vein trunk (Vp4) or high tumor burden (HTB). Methods A total of 309 patients with BCLC stage B or C HCC who received Dur/Tre between March 2023 and October 2024 were included. HTB was defined as the presence of at least one of the following radiological findings: ≥ 50% liver involvement by HCC, bile duct invasion, or the presence of Vp4. Results Both the patients with Vp4 and HTB‐positive group had significantly higher proportions of BCLC stage C disease ( p = 0.01 and 0.007, respectively) and serum DCP levels ≥ 100 mAU/mL ( p = 0.03 and < 0.001, respectively), and significantly higher neutrophil‐to‐lymphocyte ratio ( p = 0.04 and p = 0.004, respectively) compared to their respective counterparts. While the objective response rate did not significantly differ between the HTB‐positive and HTB‐negative groups (21.6% vs. 16.2%, p = 0.5), it was significantly higher in patients with Vp4 than in those without (42.9% vs. 15.6%, p = 0.02). There were no significant differences in progression‐free survival or overall survival (OS) between patients with and without Vp4 ( p = 0.1 and 0.3, respectively) and nor between the HTB‐positive and HTB‐negative groups (both p = 0.3). Among patients with both Vp4 and HTB, responders had longer OS than non‐responders. Conclusions Dur/Tre may be a viable treatment option for patients with Vp4 and HTB.

Year:

2025

This study aimed to investigate whether initiating oral care more than 2 weeks before surgery could prevent postoperative infections, particularly pneumonia. This retrospective observational study analyzed 1,806 patients who underwent surgery at the Ehime University Hospital between April 2019 and March 2023. The patients were divided into two groups: those receiving structured oral care at least 2 weeks before surgery (n = 257) and those receiving late or no oral care (n = 1,549). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to minimize selection bias. Nevertheless, residual confounding factors, especially confounding by indication, may remain, because as patients who received early oral care may differ systematically from those who did not. The primary outcome measure was the incidence of postoperative pneumonia. After PSM and IPTW analyses, the early oral care group showed significantly lower rates of postoperative pneumonia than the control group (risk difference: −3.56%, 95% confidence interval [CI]: −4.89% to −2.23%, p = 0.0004 in the matched analysis; −3.68%, 95% CI: −4.61% to −2.75%, p < 0.001 in the IPTW analysis). IPTW analysis demonstrated shorter hospital stays in the early oral care than in the control group (mean difference: −2.65 days, 95% CI: −4.75 to −0.55, p = 0.013). Implementing structured oral care at least 2 weeks before surgery reduced postoperative pneumonia and shortened hospital stays across various surgical procedures, suggesting its value as a preventive strategy for improving surgical outcomes.

Year:

2025

Aims: Sustained virological response (SVR) is a favorable prognostic factor for patients with hepatocellular carcinoma (HCC) caused by hepatitis C virus (HCV) treated curatively. This study aimed to evaluate the impact of SVR on atezolizumab plus bevacizumab (Atez/Bev) therapy for unresectable HCC (uHCC) caused by HCV. Methods: A retrospective analysis of 364 uHCC patients treated with Atez/Bev (September 2020–April 2025) and divided into SVR (n = 284) and non-SVR (n = 80) groups was performed, with clinical characteristics, prognosis, and adverse events compared. Results: There were no significant differences between the groups for age, sex, platelet count, AFP, or BCLC stage. However, the SVR group showed a significantly better ALBI score (−2.50 vs. −2.16) and lower AST (33 vs. 57 IU/L) and ALT (23 vs. 40 IU/L) levels (p < 0.01). Median progression-free survival (PFS) was 7.1 months in the SVR group and 6.1 months in the non-SVR group (p = 0.443), and median overall survival (OS) was 20.9 months in the SVR group and 18.9 months in the non-SVR group, with no significant differences between the groups (p = 0.560). Following IPW adjustment for factors related to OS, there was no significant difference regarding PFS (p = 0.921) and OS (p = 0.927). Multivariate analysis identified age ≥75 years and poor hepatic function (mALBI grade 2b/3) as independent predictors of poor OS; SVR status was not an independent factor. Changes in ALBI and Child-Pugh scores over time were not significantly different between the groups. In the non-SVR group, adverse events were more common as compared to the SVR group, including liver dysfunction (27.5% vs. 13.0%, p < 0.001) and edema/ascites (12.5% vs. 9.2%, p = 0.015). Conclusions: Although SVR was not independently associated with better survival, patients with SVR had preserved liver function and experienced fewer adverse events. These factors may indirectly support improved tolerability and therapeutic options during Atez/Bev therapy for HCV-related uHCC.

Year:

2025

Aim To evaluate the safety and efficacy of durvalumab plus tremelimumab (Dur/Tre) in older adults with unresectable hepatocellular carcinoma (HCC). Methods A total of 345 patients with HCC who received Dur/Tre were included in this study. Using propensity score matching, we compared outcomes between older (aged ≥ 75 years; n = 120) and younger individuals ( n = 120). Results The median progression‐free survival (PFS) was 3.3 months in the older group and 4.5 months in the younger group ( p = 0.271). The median overall survival (OS) was 17.0 months in older individuals and 19.2 months in younger individuals ( p = 0.598). No statistically significant differences were observed in the therapeutic response between the two groups ( p = 0.264). Additionally, the incidence of immune‐mediated adverse events (AEs) did not differ significantly between older and younger individuals. Multivariate analyses revealed that age group (older vs. younger) was not an independent prognostic factor for PFS ( p = 0.250) or OS ( p = 0.489). In a subgroup analysis stratifying older individuals into three age categories (75–79, 80–84, and ≥ 85 years), no significant differences were observed in the cumulative OS or PFS across the subgroups ( p = 0.308 and 0.783). Similarly, the incidence of immune‐mediated AEs did not differ significantly among the age categories. Conclusions Dur/Tre appears to be a safe and effective treatment option for patients with HCC, regardless of age. Dur/Tre appears to be a safe and effective treatment option for patients with unresectable HCC, regardless of age.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (22)

Sheikh Akbar

Researcher

Ehime University Graduate School of Medicine

JAPAN
View details

Yoshihiro Kamada

Osaka University

JAPAN
View details

Hisashi Kosaka

Kansai Medical University

JAPAN
View details

Hong Jae Chon

Associate Professor

CHA Bundang Medical Center

SOUTH KOREA
View details

Bunzo Matsuura

Professor

Ehime University Graduate School of Medicine

JAPAN
View details

Roger Le Grand

Head of IDMIT Department

CEA

FRANCE
View details

Naoya Sakamoto

-

JAPAN
View details

Maryline BOURGINE

Institut Pasteur

FRANCE
View details

Asahiro Morishita

Assistant Professor

Kagawa University Faculty of Medicine

JAPAN
View details

Shan He

University of Birmingham

UNITED KINGDOM
View details

Kazuo Hara

Director

Aichi Cancer Center

JAPAN
View details

Changhoon Yoo

University of Ulsan College of Medicine

SOUTH KOREA
View details

Masatoshi Kudo

Professor and Chairman

Kindai University Faculty of Medicine

JAPAN
View details

Hidenao Noritake

Hamamatsu University School of Medicine

JAPAN
View details

Yasuhito Tanaka

M.D., Ph.D

Kumamoto University

JAPAN
View details

Junko Tanaka

Prof and Chair/Head of medical School/

Hiroshima University

JAPAN
View details

Takashi Nishimura

Hyogo medical university

JAPAN
View details

Hiroki Nishikawa

-

JAPAN
View details

Andrea Casadei-Gardini

Ospedale San Raffaele

ITALY
View details

Masanori Abe

Ehime University

JAPAN
View details

Teruki Miyake

lecturer

Ehime University Graduate School of Medicine

JAPAN
View details

Masaki Kaibori

Professor

Kansai Medical University

JAPAN
View details